21 completed, 7 unknown, 2 not yet recruiting, 2 recruiting. 35 Phase 2, 9 Phase 1, 4 Phase 3.
Follow ADHD: new trials by email Literature Review of ADHD trials Research Report on ADHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep Ferrous Sulfate, Placebo - ADHD, Sleep Problems | Phase 1 / Phase 2 | Not yet recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 70 | 2027-03-01 | 2026-05-04 |
| A Clinical Trial Evaluating Fecal Microbiota Transplantation (FMT) in Adolescents With ADHD Fecal Microbiota Transplant (FMT), Nitazoxanide 500mg BID, Vancomycin 250mg BID - ADHD, ADHD - Attention Deficit Disorder With Hyperactivity | Phase 2 | Not yet recruiting | University of Calgary | 64 | 2026-08-31 | 2026-09-10 |
| A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder NRCT-101SR, NRCT-202XR - ADHD | Phase 2 | Terminated | Neurocentria, Inc. | 2 | 2025-02-25 | 2026-01-15 |
| Dual-target iTBS for Youth With ADHD TMS - ADHD | Phase 1 / Phase 2 | Recruiting | Shanghai Mental Health Center | 15 | 2025-01-01 | 2025-07-24 |
| Black Seed Oil in ADHD Atomoxetine, Black Seed Oil Cap/Tab - ADHD | Phase 2 | Unknown | Ain Shams University | 60 | 2024-10-01 | 2024-08-09 |
| Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Sertraline, Placebo - Neurodevelopmental Disorders, Autism | Phase 2 | Recruiting | Holland Bloorview Kids Rehabilitation Hospital | 130 | 2024-09-16 | 2026-07-27 |
| Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD) NRCT-101-SR, Placebo - ADHD | Phase 2 / Phase 3 | Completed | Neurocentria, Inc. | 223 | 2023-02-25 | 2025-06-03 |
| Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD Cannabis oil - ADHD, Hyperactivity | Phase 2 | Terminated | Brlev Agricultural Crops Ltd | 8 | 2022-07-31 | 2023-04-25 |
| Effectiveness of a Digital Strategy-based Educational Skills Group for Secondary Students With Organization and Academic Motivation Challenges BPT/OST, Peer Support - ADHD | Phase 2 / Phase 3 | Withdrawn | Seattle Children's Hospital | 2022-05-18 | 2026-04-24 | |
| Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial MM120, Placebo - ADHD, Attention Deficit Disorder | Phase 2 | Completed | Definium Therapeutics US, Inc. | 53 | 2021-12-17 | 2026-02-27 |
| CTx-1301 Comparative Bioavailability Study Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release - ADHD | Phase 1 / Phase 2 | Completed | Cingulate Therapeutics | 45 | 2019-12-06 | 2021-04-08 |
| Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) Amphetamine Extended Release (ER) Tablet 20 mg - ADHD | Phase 2 | Completed | Tris Pharma, Inc. | 41 | 2019-10-01 | 2022-02-18 |
| Single-dose Potassium Supplementation in Patients With ADHD for Whom the Anesthetic Lidocaine is Ineffective Potassium Gluconate Oral Capsule, Placebo oral capsule - ADHD | Phase 1 / Phase 2 | Unknown | AlkaliDx, Inc. | 100 | 2018-07-01 | 2018-06-20 |
| Motivated Behavior in Adults With and Without ADHD ADHD methylphenidate first, placebo second, ADHD placebo first, methylphenidate second, Non-ADHD methylphenidate first, placebo second - ADHD | Phase 2 | Completed | University of Arkansas | 51 | 2016-03-07 | 2021-08-27 |
| L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD L-Threonic Acid Magnesium Salt (L-TAMS) - Attention Deficit/Hyperactivity Disorder, ADHD | Phase 2 | Completed | Massachusetts General Hospital | 20 | 2016-03-01 | 2018-05-14 |
| A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ) MG01CI (1400 mg), placebo - ADHD, Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type | Phase 2 / Phase 3 | Completed | Alcobra Ltd. | 300 | 2014-03-01 | 2017-03-28 |
| Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD) V81444, Placebo - ADHD | Phase 1 / Phase 2 | Completed | Vernalis (R&D) Ltd | 31 | 2013-07-01 | 2016-06-03 |
| AR08 for Treatment of ADHD in Children AR08, Placebo - ADHD | Phase 2 | Completed | Arbor Pharmaceuticals, Inc. | 122 | 2013-06-01 | 2015-12-09 |
| Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD) GlyTI-M, Placebo - ADHD | Phase 2 | Completed | Mackay Memorial Hospital | 116 | 2012-04-01 | 2013-07-16 |
| A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) TD-9855, Placebo - Attention-Deficit/Hyperactivity Disorder, ADHD | Phase 2 | Completed | Theravance Biopharma | 295 | 2011-12-01 | 2022-04-04 |
Showing 20 of 35. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (35) · Cocaine-Related Disorders (2) · Neurodevelopmental Disorders (2) · 22q11 Deletion Syndrome (1) · Anxiety Disorders (1) · Asperger Syndrome (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Brain Injuries, Traumatic (1) · Cerebral Palsy (1) · Cognition Disorders (1) · Conduct Disorder (1) · Depression (1) · DiGeorge Syndrome (1) · Dyslexia (1)
Attention Deficit and Disruptive Behavior Disorders (35) · Mental Disorders (35) · Neurodevelopmental Disorders (33) · Nervous System Diseases (5) · Neurologic Manifestations (4) · Pathological Conditions, Signs and Symptoms (4) · Behavior (3) · Neurobehavioral Manifestations (3) · Signs and Symptoms (3) · Behavioral Symptoms (2) · Brain Diseases (2) · Cardiovascular Diseases (2) · Central Nervous System Diseases (2) · Chemically-Induced Disorders (2) · Child Development Disorders, Pervasive (2)
Atomoxetine Hydrochloride (3) · Methylphenidate (2) · Tablets (2) · 3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo(3.2.0)heptane (1) · BID protein, human (1) · Bupropion (1) · Capsules (1) · Cognitive Remediation (1) · Dexmethylphenidate Hydrochloride (1) · Dextroamphetamine (1) · Fecal Microbiota Transplantation (1) · Lisdexamfetamine Dimesylate (1) · Modafinil (1) · Pico-Salax (1) · Selective Serotonin Reuptake Inhibitors (1)
Alcobra Ltd. (2) · Neurocentria, Inc. (2) · Abbott (1) · Ain Shams University (1) · AlkaliDx, Inc. (1) · Arbor Pharmaceuticals, Inc. (1) · AstraZeneca (1) · Brlev Agricultural Crops Ltd (1) · Cephalon (1) · Cingulate Therapeutics (1) · Definium Therapeutics US, Inc. (1) · Holland Bloorview Kids Rehabilitation Hospital (1) · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (1) · Mackay Memorial Hospital (1) · Massachusetts General Hospital (1)
United States (21) · Israel (5) · Canada (2) · Brazil (1) · China (1) · Germany (1) · Netherlands (1) · Poland (1) · Switzerland (1) · Taiwan (1)
Alison E Pritchard, PhD (1) · Anil Chacko, PhD (1) · Bradley Vince, MD (1) · Craig Surman, MD (1) · Debora Arnaut, PSYD (1) · Dr. Evdokia Anagnostou (1) · Earle Bain, MD (1) · Frances R Levin, M.D. (1) · Guosong Liu, M.D., Ph.D. (1) · Guy Bar-Klein, PhD (1) · Iris Manor, MD (1) · Jean G Gehricke, Ph.D. (1) · Joseph Biederman, MD (1) · Kim Kuypers (1) · Laurence Downey, MD (1)
PMID 16102908, PMID 21356232, PMID 23106988, PMID 23290324, PMID 23856296, PMID 23933905, PMID 24117656, PMID 25436448, PMID 25505396, PMID 25733754, PMID 28576350, PMID 30659782, PMID 31226260, PMID 31677152, PMID 32731812, PMID 32781397, PMID 32856281, PMID 36061275, PMID 36548042, PMID 37058600, PMID 37385583, PMID 40105807, PMID 42322409, PMID 42518155
R01DA011444 (1)